Trevena Inc (TRVN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Trevena Inc (TRVN) has a cash flow conversion efficiency ratio of 0.193x as of September 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.50 Million) by net assets ($-23.31 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Trevena Inc for the company's overall valuation and market capitalisation.
Trevena Inc - Cash Flow Conversion Efficiency Trend (2011–2023)
This chart illustrates how Trevena Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Trevena Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Trevena Inc ranked by their cash flow conversion efficiency. See TRVN cash flow to debt ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Yugo Metals Limited
AU:YUG
|
N/A |
|
Ordinary Fully Paid Deferred Settlement
AU:IPTDA
|
N/A |
|
Auddia Inc
NASDAQ:AUUDW
|
-0.436x |
|
CareMax Inc
NASDAQ:CMAX
|
0.165x |
|
Pure One Corporation Limited
AU:P1E
|
-0.273x |
|
Mammoth Minerals Limited
AU:M79
|
N/A |
|
Keras Resources PLC
LSE:KRS
|
-0.132x |
|
Biocept Inc.
NASDAQ:BIOCQ
|
-10.641x |
Annual Cash Flow Conversion Efficiency for Trevena Inc (2011–2023)
The table below shows the annual cash flow conversion efficiency of Trevena Inc from 2011 to 2023. View today's stock price for Trevena Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $-7.66 Million | $-33.03 Million | 4.314x | +230.74% |
| 2022-12-31 | $15.60 Million | $-51.48 Million | -3.300x | -324.88% |
| 2021-12-31 | $64.63 Million | $-50.20 Million | -0.777x | -277.81% |
| 2020-12-31 | $104.07 Million | $-21.39 Million | -0.206x | +73.87% |
| 2019-12-31 | $30.08 Million | $-23.67 Million | -0.787x | -28.77% |
| 2018-12-31 | $41.53 Million | $-25.38 Million | -0.611x | +70.30% |
| 2017-12-31 | $34.63 Million | $-71.25 Million | -2.057x | -76.59% |
| 2016-12-31 | $78.58 Million | $-91.55 Million | -1.165x | -316.12% |
| 2015-12-31 | $143.13 Million | $-40.07 Million | -0.280x | +30.17% |
| 2014-12-31 | $99.20 Million | $-39.78 Million | -0.401x | +35.50% |
| 2013-12-31 | $38.99 Million | $-24.24 Million | -0.622x | -100.16% |
| 2012-12-31 | $-39.18K | $-14.81 Million | 377.866x | +43962.15% |
| 2011-12-31 | $15.42 Million | $-13.28 Million | -0.861x | -- |
About Trevena Inc
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the… Read more